19 C
February 21, 2024
The Hona News

First MYC inhibitor to demonstrate safety and anti-tumor activity in a phase I first-in-human clinical trial

Directed by Laura Soucek, an ICREA Research Professor, Director of VHIO’s Experimental Therapeutics Program and head of our Models of Cancer Therapies Group, two decades of research aimed at combating resistance to therapy and cancer regression through inhibiting the MYC oncogene—found deregulated in most, if not all tumor types—has led to the in-house development of the Omomyc (OMO-103) therapeutic mini-protein by the VHIO and Catalan Institute of Research and Advanced Studies’ (ICREA) spin-off company Peptomyc S.L., which Soucek co-founded in 2014 alongside Marie-Eve Beaulieu, Peptomyc’s Chief Scientific Officer.

Source link

Related posts

Teaching positive psychology skills at school may be one way to help student mental health and happiness


How obesity dismantles our mitochondria: Study reveals key mechanism behind obesity-related metabolic dysfunction


Insulin prices in US are nine times higher than in other wealthy nations, report finds


Leave a Comment